Two Sigma Investments LP Has $2.09 Million Stock Holdings in Editas Medicine, Inc. (NASDAQ:EDIT)

Two Sigma Investments LP increased its position in shares of Editas Medicine, Inc. (NASDAQ:EDIT - Free Report) by 21.4% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,649,072 shares of the company's stock after purchasing an additional 290,483 shares during the quarter. Two Sigma Investments LP owned approximately 2.00% of Editas Medicine worth $2,094,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Invesco Ltd. grew its stake in Editas Medicine by 9.2% during the fourth quarter. Invesco Ltd. now owns 100,164 shares of the company's stock worth $127,000 after buying an additional 8,448 shares during the last quarter. Intech Investment Management LLC boosted its holdings in shares of Editas Medicine by 43.1% in the 4th quarter. Intech Investment Management LLC now owns 40,942 shares of the company's stock worth $52,000 after acquiring an additional 12,336 shares in the last quarter. Dark Forest Capital Management LP grew its position in Editas Medicine by 66.9% during the 4th quarter. Dark Forest Capital Management LP now owns 32,787 shares of the company's stock worth $42,000 after acquiring an additional 13,138 shares during the last quarter. JPMorgan Chase & Co. grew its position in Editas Medicine by 2.1% during the 4th quarter. JPMorgan Chase & Co. now owns 787,599 shares of the company's stock worth $1,000,000 after acquiring an additional 16,419 shares during the last quarter. Finally, Ieq Capital LLC acquired a new stake in Editas Medicine during the 4th quarter valued at $31,000. 71.90% of the stock is owned by institutional investors.

Editas Medicine Stock Down 1.1%

EDIT stock traded down $0.02 during midday trading on Thursday, reaching $1.80. The company's stock had a trading volume of 3,176,169 shares, compared to its average volume of 2,565,412. The business's 50-day simple moving average is $1.45 and its 200-day simple moving average is $1.53. Editas Medicine, Inc. has a 52 week low of $0.91 and a 52 week high of $6.22. The stock has a market cap of $150.68 million, a PE ratio of -0.70 and a beta of 2.15.

Editas Medicine (NASDAQ:EDIT - Get Free Report) last posted its quarterly earnings results on Monday, May 12th. The company reported ($0.43) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.51) by $0.08. The business had revenue of $4.66 million for the quarter, compared to analyst estimates of $0.79 million. Editas Medicine had a negative return on equity of 80.13% and a negative net margin of 340.96%. During the same period last year, the company earned ($76.00) EPS. As a group, equities analysts forecast that Editas Medicine, Inc. will post -2.71 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have commented on EDIT. Wall Street Zen raised Editas Medicine from a "sell" rating to a "hold" rating in a research note on Wednesday, May 14th. HC Wainwright initiated coverage on Editas Medicine in a report on Monday, April 28th. They issued a "buy" rating and a $3.00 price target for the company. Cantor Fitzgerald raised shares of Editas Medicine from a "hold" rating to a "strong-buy" rating in a report on Tuesday, April 29th. Finally, Robert W. Baird lowered their price objective on shares of Editas Medicine from $8.00 to $4.00 and set an "outperform" rating for the company in a research report on Tuesday, May 13th. Two investment analysts have rated the stock with a sell rating, nine have given a hold rating, two have issued a buy rating and two have given a strong buy rating to the company's stock. Based on data from MarketBeat, Editas Medicine currently has an average rating of "Hold" and a consensus price target of $5.36.

Insiders Place Their Bets

In other news, CEO Gilmore Neil O'neill sold 15,192 shares of Editas Medicine stock in a transaction on Tuesday, June 3rd. The shares were sold at an average price of $1.72, for a total transaction of $26,130.24. Following the transaction, the chief executive officer now directly owns 280,282 shares of the company's stock, valued at $482,085.04. This trade represents a 5.14% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Over the last quarter, insiders have sold 16,364 shares of company stock worth $28,146. Insiders own 2.10% of the company's stock.

About Editas Medicine

Editas Medicine, Inc, a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia.